Skip to content

Comparison of the Integrated Posterior-Anterior-Lateral Approach and the Posterior Approach in Robotic Radical Prostatectomy

A Prospective, Randomized Controlled Study Comparing the Integrated Posterior-Anterior-Lateral (PAL) Approach and the Posterior Approach in Robot-Assisted Radical Prostatectomy: Evaluation of Perioperative Outcomes, Postoperative Functional Recovery, and Oncologic Control

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07305142
Enrollment
60
Registered
2025-12-26
Start date
2024-05-16
Completion date
2025-12-02
Last updated
2025-12-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate, Robot Assisted Laparoscopic Radical Prostatectomy, Urologic Cancer

Brief summary

This study aims to compare perioperative, pathological, and early functional outcomes of PAL (Posterior, Anterior and Lateral)combined approach RARP and posterior approach (with Retzius space preserved) RARP in the treatment of prostate cancer.The main question it aims to answer was: What is the early therapeutic efficacy of robot-assisted laparoscopic radical prostatectomy using the combined posterior, anterior, and lateral (PAL) approach, and how does it compare with the traditional posterior approach? Participants were randomly assigned to undergo either robot-assisted laparoscopic radical prostatectomy using the PAL (posterior-anterior-lateral) approach or the classic posterior approach.

Interventions

PROCEDUREPAL combined approach group

PAL combined approach was performed to resect the prostate

PROCEDUREposterior approach group

Intraoperative resection of the prostate was performed by posterior approach

Sponsors

The First Affiliated Hospital of Zhengzhou University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
40 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Prostate biopsy confirms prostate cancer; * Clinical T stage \<=T3a stage; * Fully understand clinical trial protocols and sign informed consent;

Exclusion criteria

* Urinary incontinence before surgery; * Previous endoscopic prostate surgery; * There are serious underlying diseases that cannot tolerate surgery or have a survival of less than 5 years; * Metastatic disease is present or lymph node involvement is suspected at diagnosis; * Patients judged by the investigator to be unsuitable for participation in this clinical trial;

Design outcomes

Primary

MeasureTime frameDescription
urinary continencePatients were assessed for urinary incontinence, defined according to established criteria, via telephone at five time points after the removal of the urinary catheter (which was 2-3 weeks post-surgery): within 7 days, and at 1, 3, 6, and 12 months.was defined as the use of zero to one safety pad per day without any involuntary leakage.Immediate continence was defined as continence within seven days after catheter removal, while early continence was defined as continence achieved within three months.

Secondary

MeasureTime frameDescription
Operation timeDuring operation
Estimated blood lossDuring operation
ComplicationsPerioperativeComplications were classified according to the Clavien-Dindo system, and those of grade II or higher were documented in this study.
Time for removal of drainage tubePerioperative

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026